Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Stefania, Braidotti"'
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
This report describes a pediatric case of isolated agranulocytosis occurring months after hematopoietic stem cell transplantation (HSCT). Secondary cytopenia, or secondary transplant failure, affects 10%–25% of HSCT recipients, with potential trigg
Externí odkaz:
https://doaj.org/article/5ef64e1147384d9c9d165dca6c67f450
Autor:
Stefania Braidotti, Marilena Granzotto, Debora Curci, Barbara Faganel Kotnik, Natalia Maximova
Publikováno v:
Biomedicines, Vol 12, Iss 8, p 1853 (2024)
Optimized use of prophylactic or therapeutic donor lymphocyte infusions (DLI) is aimed at improving clinical outcomes in patients with malignant and non-malignant hematological diseases who have undergone allogeneic hematopoietic stem cell transplant
Externí odkaz:
https://doaj.org/article/e724ab7d952543bc85fe38b663375f3e
Autor:
Stefania Braidotti, Debora Curci, Daniele Zampieri, Cesare Covino, Davide Zanon, Natalia Maximova, Roberto Sala
Publikováno v:
Biomedicines, Vol 11, Iss 11, p 2940 (2023)
Oligodendroglioma (OG) is a brain tumor that contributes to
Externí odkaz:
https://doaj.org/article/d741989bc1c84bffacde736dece461af
Autor:
Oksana Montecchini, Stefania Braidotti, Raffaella Franca, Giulia Zudeh, Christian Boni, Claudio Sorio, Eleonora Toffoletti, Marco Rabusin, Alberto Tommasini, Giuliana Decorti, Gabriele Stocco
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
The pathogenic role of the overactivated ABL1 tyrosine kinase (TK) pathway is well recognized in some forms of BCR-ABL1 like acute lymphoblastic leukemia (ALL); TK inhibitors represent a useful therapeutic choice in these patients who respond poorly
Externí odkaz:
https://doaj.org/article/b3cbf4c74ffc49329cb1727d6d00ffbb
Autor:
Stefania Braidotti, Raffaella Franca, Marilena Granzotto, Elisa Piscianz, Alberto Tommasini, Marco Rabusin, Gabriele Stocco, Giuliana Decorti
Publikováno v:
Frontiers in Bioscience-Landmark, Vol 27, Iss 2, p 039 (2022)
Background: The T-cell engager antibody blinatumomab (BlincytoTM) represents a promising rescue therapy for relapsed/refractory CD19+ acute lymphoblastic leukemia (B-ALL), although ~20–30% of patients still do not respond to treatment. Blinatumo
Externí odkaz:
https://doaj.org/article/36966ce399ad48d1b3f92178fee1506e
Autor:
Giuliana Decorti, Gabriele Stocco, Marco Rabusin, Alberto Tommasini, Elisa Piscianz, Marilena Granzotto, Raffaella Franca, Stefania Braidotti
Background: The T-cell engager antibody blinatumomab (BlincytoTM) represents a promising rescue therapy for relapsed/refractory CD19+ acute lymphoblastic leukemia (B-ALL), although ∼20-30% of patients still do not respond to treatment. Blinatumomab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c15dd96acace8c0958d00c964de68403
https://www.imrpress.com/journal/FBL/27/2/10.31083/j.fbl2702039
https://www.imrpress.com/journal/FBL/27/2/10.31083/j.fbl2702039
Autor:
Stefania, Braidotti, Raffaella, Franca, Marilena, Granzotto, Elisa, Piscianz, Alberto, Tommasini, Marco, Rabusin, Gabriele, Stocco, Giuliana, Decorti
Publikováno v:
Frontiers in bioscience (Landmark edition). 27(2)
The T-cell engager antibody blinatumomab (BlincytoTM) represents a promising rescue therapy for relapsed/refractory CD19+ acute lymphoblastic leukemia (B-ALL), although ~20-30% of patients still do not respond to treatment. Blinatumomab creates a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a09bfdd0a67295b12f295c08d133b4b0
https://pubmed.ncbi.nlm.nih.gov/35226982
https://pubmed.ncbi.nlm.nih.gov/35226982